The demographic and clinical features in patients with systemic sclerosis.
| Characteristic | Baseline |
| Age at diagnosis* | 48±13.7 |
| Female sex, n (%) | 131 (89.7) |
| Duration of follow-up, months** | 71 (6-228) |
| Disease subtype, n (%) | |
| Diffuse / Limited | 66 (45.2) / 80 (54.8) |
| Autoantibodies, n (%) | |
| Anti-Scl70 antibody | 50/143 (35.0) |
| Anti-Centromere antibody | 62/143 (43.4) |
| Immunsuppresive medication, ever, n (%) | |
| Hydroxychloroquine | 91/143 (63.6) |
| Mycophenolate mofetil | 18/145 (12.4) |
| Azathioprine | 47/145 (32.4) |
| Cyclophosphamide | 24/145 (16.6) |
| Glucocorticoid | 80/140 (57.1) |
| Others, n (%) | |
| ILD | 68/130 (52.3) |
| Pericardial effusion, ever | 26/133 (19.5) |
| Esophageal dilation (detected by CT) | 51/128 (39.8) |
| sPAP ≥35mmHg, ever (measured by ECHO) | 46/142 (32.4) |
*Parameter presented as mean±SD
**Parameter presented as median (min-max)
CT, computed tomography; ECHO, echocardiogram; ILD, interstitial lung disease; sPAP, systolic pulmonary artery pressure